Inozyme Pharma to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the following investor conferences:
Related news for (INZY)
- 24/7 Market News Snapshot 16 May, 2025 – Inozyme Pharma, Inc. Common Stock (NASDAQ:INZY)
- Top Breakout Stocks to Trade: Amesite, Siyata Mobile, Quantum Computing, Archer Aviation, Inozyme Pharma, and Applied Digital
- 24/7 Market News Snapshot 16 May, 2025 – Inozyme Pharma, Inc. Common Stock (NASDAQ:INZY)
- Don’t Miss Out: MoBot’s Latest Stock Updates 05/16/25 08:00 AM
- Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights